(FM) Inmunología
Departamento académico
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (11)
2024
-
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3
-
Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma
OncoImmunology, Vol. 13, Núm. 1
-
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4
2022
-
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781
2021
-
Preclinical development of a humanized chimeric antigen receptor against B-cell maturation antigen for multiple myeloma
Haematologica, Vol. 106, Núm. 1, pp. 173-184
-
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 9
2015
-
Consensus nomenclature for CD8+ T cell phenotypes in cancer
OncoImmunology, Vol. 4, Núm. 4
-
Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014
Journal of Translational Medicine, Vol. 13, Núm. 1
2014
-
Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013
Journal of Translational Medicine, Vol. 12, Núm. 1
2011
-
Defining the critical hurdles in cancer immunotherapy
Journal of Translational Medicine
2010
-
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009
Cancer Immunology, Immunotherapy